Workday Shares Climb After Q4 Report: Here’s Why
Workday reported its fourth-quarter results after Tuesday’s closing bell. Here’s a look at the details from the report: read more
Read More
Cava Group Stock Drops After Q4 Earnings Miss: Details
CAVA Group reported its fourth-quarter results after Tuesday’s closing bell. Here’s a look at the key figures from the quarter: read more
Lucid Q4 Earnings: Revenue Beat, EPS Beat, 20K Production Guidance For 2025, CEO Transition And More
Lucid reports fourth-quarter revenue of $234.5 million, beating the consensus estimate of $214.22 million, according to Benzinga Pro. read more
Lung Disease-Focused Insmed ‘Is An Attractive Midcap Biotech,’ Analyst Says
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib’s launch potential and Arikayce’s growth. FDA decision on brensocatib due August 2025. Latest Ratings for INSM Date Firm Action From To Feb 2022 SVB Leerink Maintains Outperform Dec 2021 JP Morgan Initiates Coverage On Overweight Oct 2021 Cantor Fitzgerald Initiates Coverage On Overweight View More…
Microsoft Trades At Discount To Oracle Despite Strong Cloud Position: Analyst
Goldman Sachs analyst reiterates Buy rating on Microsoft Corp with $500 price target and unchanged fiscal 2025/2026 estimates due to AI data center lease adjustments. Latest Ratings for MSFT Date Firm Action From To Feb 2022 Tigress Financial Maintains Buy Jan 2022 Citigroup Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings…
Solventum Shares Are Up Today: What’s Going On?
Solventum shares are trading higher Tuesday after the company announced it will sell its purification and filtration business to Thermo Fisher for $4.1 billion in cash. read more
EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD
Enveric Biosciences secures a U.S. patent for non-hallucinogenic mescaline derivatives targeting addiction, ADHD and anxiety. read more
